Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by bionicjoeon Sep 30, 2018 9:47am
129 Views
Post# 28716726

RE:RE:RE:RE:SESN...

RE:RE:RE:RE:SESN...
fredgoodwinson wrote:

Theralase will be trying to get into Phase II asap but since we now require another ITA  (a modification for the real-time monitoring of PLIM/FLIM?) the Company could help itself a lot just by releasing the information that this has actually been applied for - if it has.

 

They thought it worth announcing the last ITA application and just to tell us this time that ITA and REB approval is anticipated ' in due course' doesn`t cut it.

 

The fastest that we have ever been granted an ITA was 84 days` for the last application and that was lightning-quick compared to previous experience.

 

If the ITA has not yet been applied for we can pretty much forget a Phase II start in the early New Year.



Fredgoodwinson, you're making a good case for investors waiting until the uncertainty clears up. Shareholders can only hope that information will be released Monday along with the status of the PP. For those that don't think having a new CEO matters then consider if it's worth you constantly not knowing what is going on. Who is running TLT, the interim CEO who is more a science guy, the CFO or is it our old friend the business development guy? Does it even matter when nothing ever seems to change in the way this company informs its shareholders?

Bullboard Posts